Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (981)	5/24/1999 3:59:00 PM
From: Mark Bong	Read Replies (1) \| Respond to of 1686

this was from the MSN article a while back. "Coleman Lannum, biotech and medical devices analyst at Putnam Investments, says he believes Biogen has some "potential blockbusters" in its pipeline worth "conservatively" hundreds of millions of dollars, but those products are at least a couple of years away from commercialization. Once a product passes through phase 1, 2 and 3 trials, it can then file an application with the FDA, which will approve or reject a drug for use by patients in the U.S. ...Amevive, a protein that inhibits T-cell function, is in phase 2 trials for psoriasis. It is expected to come to market in the first half of 2002 with a (world) market potential of $3.6 billion, according to Rauch..." I would offer my guess that the potential for the BGEN drug is over $1B, but, as you know, it usually takes years to develop the market potential of a new drug. My guess is that ML sees the potential in years 2-4 after launch as (conservatively) $300-500 in the US market alone.